NPS RADARhelps Prescribers Navigate Decision-making

Prescribers considering use of zoledronic acid (Aclasta) once-yearly infusion in patients who have osteoporosis will need to weigh up the possible benefits against the relative lack of experience with this drug in osteoporosis. This month’s NPS RADAR review of the newly PBS-listed drug provides information to help prescribers’ decision-making and to counsel patients.

More: continued here

Filed under: Bones on December 11th, 2008